louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01942850: International Ataxia Rating Scale in Younger Patients
Official title: APPLICABILITY OF THE INTERNATIONAL ATAXIA RATING SCALE (ICARS) IN YOUNGER PATIENTS AND DEVELOPMENT OF GLOBAL RATING INSTRUMENTS FOR PATIENTS WITH ATAXIA TELANGIECTASIA (AT)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Ataxia Telangiectasia
Lead sponsor: Quince Therapeutics S.p.A.
Sponsor class: INDUSTRY
First posted: 2013-09-16
Enrollment: 63
Sex: ALL
Minimum age (years): 6
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Known patients with ataxia/ataxia telangiectasia

Brief summary: The project will collect information on the mapping of clinical ratings on a number of scales that are used in the assessment of patients with ataxias.


Eligibility criteria: Inclusion criteria

1. Patients aged 6-18 years with diagnosed with ataxia, preferably AT will be included. The diagnosis of AT will be made based on the criteria: typical clinical picture plus one of the following: 1. a proven mutation in the ATM gene 2. Deficient ATM protein proven by Western blotting 3. Elevated α-fetoprotein, cerebellar atrophy on MRI and immune deficiency/ chromosomal breakage/ T- cell lymphoreticular malignancy.
2. Children aged 6-18 years with suspected AT (fulfilling partially the above criteria will be included)
3. Children aged 6-18 years with AT like disease, with or without proven mutation in the MRE11 gene will be included
4. Children aged 6-18 years of age with ataxia of other known or unknown etiologies might be included, but their total number should not exceed 20% of the cohort in each site

Primary outcomes:
measure: Correlation Analysis
timeFrame: single visit
Secondary outcomes:
Other outcomes:
Locations:
city: Tampa
country: United States
facility: Carol Morsani USF Health Center
state: Florida
city: Mumbai
country: India
facility: Jaslok Hospital
city: Tel Hashomer
country: Israel
facility: Edmond and Lilly Safra Childrens Hospital Pediatric Unit
city: Brescia
country: Italy
facility: A.O Spedalli Civilli Brescia
city: Roma
country: Italy
facility: Università La Sapienza
Study officials:
affiliation: Quince Therapeutics S.p.A.
name: Luca Benatti, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT04342650: Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection
Official title: Phase IIb Study to Evaluate the Efficacy and Safety of Chloroquine Diphosphate in the Treatment of Patients With Comorbidities, Without Severe Acute Respiratory Syndrome, Under the New Coronavirus (SARS-CoV2): a Double-blind, Randomized, Placebo-controlled Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: COVID-19
SARS-CoV Infection
Severe Acute Respiratory Syndrome (SARS) Pneumonia
Clinical Trial
Lead sponsor: Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
Sponsor class: OTHER
First posted: 2020-04-13
Enrollment: 152
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a double-blind, randomized, placebo-controlled clinical trial. A total of 210 individuals aged over 18 years old, without a diagnosis of severe respiratory disease, who came to the study site with clinical and radiological suspicion of SARS-CoV2, will be randomized into two treatment groups at a 1:1 ratio to receive a 5-day CQ diphosphate tablets or placebo (tablet without active ingredient produced with the same physical characteristics).


Eligibility criteria: Inclusion Criteria:

1. Suspected cases of COVID-19, due to clinical and radiological data, during the epidemic;
2. Adult aged 18 or over, at the time of inclusion
3. Not having severe acute respiratory syndrome (SARS), that is, not using mechanical ventilation or supplemental oxygen, peripheral oxygen saturation\> 94% in room air, and having a respiratory rate below 24 incursions per minute.
4. Patients with comorbidities only, due to the increased risk of developing SARS

Exclusion Criteria:

1. Patients with chronic use of drugs known to prolong QTc interval.

Primary outcomes:
measure: Proportion of patients with onset of severe acute respiratory syndrome (SARS)
timeFrame: 7 days after randomization
Secondary outcomes:
measure: Mortality rate
timeFrame: after randomization, up to 28 days
measure: Number of participants in need of intensive care support
timeFrame: during and after intervention, up to 28 days
measure: Viral concentration
timeFrame: After randomization, up to 7 days
measure: Cumulative incidence of serious adverse events
timeFrame: During and after intervention, up to 28 days
measure: Cumulative incidence of grade 3 and 4 adverse events
timeFrame: During and after intervention, up to 28 days
measure: Proportion of patients with discontinued treatment
timeFrame: after randomization, up to 28 days
measure: Incidence of cardiac lesions
timeFrame: after randomization, up to 120 days
measure: Incidence of cardiac disfunctions
timeFrame: after randomization, up to 120 days
measure: Change in respiratory capacity
timeFrame: Day 120 after randomization
Other outcomes:
Locations:
city: Manaus
country: Brazil
facility: Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz
state: Amazonas
Study officials:
References:
Clinical trial NCT05133050: Safety and Efficacy of ACEI in Alport Syndrome Patients With COL4A3/COL4A4/COL4A5 Variants
Official title: Safety and Efficacy of Early Angiotensin-converting Enzyme Inhibition in Patients With Alport Syndrome Carrying Pathogenic Heterozygous COL4A3,COL4A4 or COL4A5 Mutations
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Alport Syndrome
Lead sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Sponsor class: OTHER
First posted: 2021-11-24
Enrollment: 510
Sex: ALL
Minimum age (years): 30
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Alport syndrome (AS) is the second most common monogenic cause of end-stage renal failure (ESRF). AS is caused by variants in the COL4A3, COL4A4, and COL4A5 genes, which encode for the a3, a4, and a5 chains of type IV collagen. This trial is a prospective, randomized, controlled and multicenter trial. Mainly to assess the safety and efficacy of ramipril in Alport syndrome patients with variants of COL4A3/COL4A4/COL4A5.


Eligibility criteria: Inclusion Criteria:

1. Age: 30-50 Years;
2. Sex: All;
3. Alport syndrome patients with variants of COL4A3/COL4A4/COL4A5; hematuria or microalbuminuria; eGFR\>90 mL/min/1.73m2;
4. Patients with microscopic hematuria only;
5. Patients with microscopic hematuria and microalbuminuria: 30-300mg/24h or urine albumin/creatinine: 30-300mg/g;
6. No angiotensin converting enzyme inhibitor (ACEI) and other renin-angiotensin system inhibitors (including angiotensin II receptor antagonists, etc.) treatment.

Exclusion Criteria:

1. With primary or secondary kidney disease, including IgA nephropathy, membranous nephropathy, lupus nephropathy, benign renal arterioles, etc.;
2. Patients with a history of angioedema;
3. Hypovolemia or hypotension (systolic blood pressure less than 90mmHg and/or diastolic blood pressure less than 60mmHg);
4. Pregnant and lactating women;
5. Patients with bilateral renal artery stenosis or unilateral renal artery stenosis with solitary kidney;
6. Hyperkalemia, blood potassium\>5.5mmol/L;
7. Severe aortic stenosis, severe mitral stenosis;
8. Treatment of drug allergy;
9. Hypertension or other diseases that may require treatment with angiotensin-converting enzyme inhibitors;
10. Disagree to participate in this research.

Primary outcomes:
measure: Disease progression time
timeFrame: Up to 240 weeks
Secondary outcomes:
measure: 5-year disease progression rate and eGFR slope
timeFrame: Up to 240 weeks
Other outcomes:
measure: Number of patients with adverse events
timeFrame: Up to 240 weeks
Locations:
city: Shanghai
country: China
facility: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Study officials:
References:
Clinical trial NCT01454050: Lumax 740 Master Study
Official title: PME/Master Study of the Lumax 740 ICD Family
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Safety and Efficacy of the Lumax 740 ICD Family
Keywords: ICD therapy
RV/LV Capture Control
Safety and Efficacy
Lead sponsor: Biotronik SE & Co. KG
Sponsor class: INDUSTRY
First posted: 2011-10-18
Enrollment: 189
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with standard ICD indication who are referred to the hospital.

Brief summary: The objective of this study is to prove the safety and efficacy of the Lumax 740 ICD family. Primarily, the newly implemented RV/LV Capture Control algorithm is evaluated, which automatically measures the RV/LV threshold and subsequently adjusts the pacing output.


Eligibility criteria: Inclusion Criteria:

* Inclusion Criteria: Standard indication for single, dual, or triple chamber ICD.

  * Legal capacity and ability to consent
  * Signed patient informed consent

In addition for HF-T devices:

* Bipolar LV-lead with a min. distance of 15 mm between tip and ring
* True bipolar RV lead

Exclusion Criteria:

* Standard contraindication for single, dual, or triple chamber ICD.

  * Age \< 18 years
  * Pregnant or breast-feeding woman
  * Cardiac surgery planned within the next 6 months
  * Life expectancy of less than 6 months
  * Participating in any other clinical study of an investigational cardiac drug or device

Primary outcomes:
measure: Efficacy of the automatic Capture Control feature
timeFrame: PHD, 1-, 3- and 6-month follow-up
Secondary outcomes:
Other outcomes:
Locations:
city: Hannover
country: Germany
facility: Medical School Hannover
Study officials:
affiliation: Herz im Zentrum Hannover, Germany
name: Gunnar Klein, Prof. Dr.
role: STUDY_CHAIR
References:
Clinical trial NCT06018350: Medication Adherence in Rheumatic Diseases
Official title: Improving Medication Adherence in Chronic Rheumatic Diseases
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Rheumatic Diseases
Lead sponsor: Duke University
Sponsor class: OTHER
First posted: 2023-08-30
Enrollment: 6
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The investigators will pilot test a clinician-led intervention to improve medication adherence in general rheumatology clinic across a spectrum of rheumatic diseases. The study will assess feasibility, acceptability, and fidelity, and explore signal for improved medication adherence.


Eligibility criteria: Inclusion Criteria:

* all providers at Southpoint Rheumatology All patients with a rheumatic disease diagnosis currently prescribed at least one rheumatic medication will be included in the analysis

Exclusion Criteria:

* new patients, those who are not prescribed any rheumatic disease medications, or do not have available pharmacy refill data

Primary outcomes:
measure: Intervention Feasibility
timeFrame: 4 weeks
measure: Intervention Feasibility
timeFrame: 4 weeks
measure: Intervention Feasibility
timeFrame: 4 weeks
Secondary outcomes:
measure: Acceptability
timeFrame: 4 weeks
measure: Acceptability, as measured by the percentage of patients who report a positive feeling after having an adherence conversation with their providers
timeFrame: 4 weeks
measure: Fidelity
timeFrame: 4 weeks
measure: Fidelity
timeFrame: 4 weeks
measure: Change in medication adherence
timeFrame: baseline, 3 months
measure: Change in medication adherence
timeFrame: baseline, 6 months
Other outcomes:
Locations:
city: Durham
country: United States
facility: Duke University
state: North Carolina
Study officials:
affiliation: Duke Health
name: Kai Sun, MD, MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02201550: Study of Immune Cells in Obese Patients With Type 2 Diabetes Mellitus Treated With Liraglutide
Official title: Regulation of Immune Cells in Obese Patients With Type 2 Diabetes Mellitus Treated With Liraglutide (Victoza)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Type 2 Diabetes Mellitus
Lead sponsor: Hvidovre University Hospital
Sponsor class: OTHER
Collaborators: name: Zealand Pharma
First posted: 2014-07-28
Enrollment: 9
Sex: MALE
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with type 2 diabetes undertaking treatment with liraglutide

Brief summary: The purpose of this study is to determine the effect of exogenous glucagon-like peptide-1 on the immune system i.e on the regulation of immune cells important in diseases such as obesity and diabetes.

The hypotheses are:

* Glucagon-like peptide-1 has an immunological effect observed by studying immune cells in the blood
* Treatment with glucagon-like peptide-1 increases the number of immune cells in the blood
* Treatment with glucagon-like peptide-1 leads to a more anti-inflammatory cytokine profile in the blood


Eligibility criteria: Inclusion Criteria:

* Type 2 diabetes
* BMI \> 27 kg/m2
* Planed start of treatment with liraglutide
* Age \> 18 years

Exclusion Criteria:

* Infection or active inflammatory disorder
* Immunomodulating treatment (i.e nonsteroidal antiinflammatory drugs, glucocorticoids)
* Smoking
* Alcohol consumption \> 14 beverages/week
* Former bariatric surgery

Primary outcomes:
measure: Change in number of specific immune cells in blood detected by flow cytometry
timeFrame: Before and 12 weeks after initiation of liraglutide treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Hvidovre
country: Denmark
facility: Hvidovre University Hospital
Study officials:
affiliation: Hvidovre University Hospital
name: Carsten Dirksen, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Hvidovre University Hospital
name: Sten Madsbad, MD, DMSc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05295550: Reliability of the Smartphone Inclinometer App and Flexicurve
Official title: Reliability of the Smartphone Inclinometer Application and Flexicurve on Thoracic Kyphosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Disorder
Kyphosis Deformity of Thoracic Spine
Lead sponsor: Hasan Kalyoncu University
Sponsor class: OTHER
First posted: 2022-03-25
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The presedent study evaluates intra-rater and inter-rater reliability of the Smartphone inclinometer app and the flexicurve, on the thoracic kyphosis

Detailed description: Sixty subjects ranging from 17to 24 years of age were evaluated by two independent evaluators using the Flexicurve and the Smartphone inclinometer app to measure thoracic kyphosis

Eligibility criteria: Inclusion Criteria:

* over 30 degree toracic kyphosis,
* 18-30 age year old,
* individuals to willing participate in the study

Exclusion Criteria:

* Skolyoz (Cobb angle 10\< ),
* rigid thoracic kyphosis,
* congenital spine disease,
* training with professional sports

Primary outcomes:
measure: İntra-İnterrater reliability fleksicurve and smartphone inclinometer app on thoracic kyphosis
timeFrame: 1 Year
Secondary outcomes:
Other outcomes:
Locations:
city: Şehi̇tkami̇l
country: Turkey
facility: Hasan Kalyoncu Üniversitesi
state: Gazi̇antep
Study officials:
affiliation: HKU
name: GÖNÜL ELPEZE
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02512250: Swiss Hemophilia Registry
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Hemophilia and Other Severe Bleeding Disorders
Lead sponsor: Swiss Hemophilia Network
Sponsor class: OTHER
First posted: 2015-07-30
Enrollment: 900
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with hemophilia and other severe bleeding disorders

Brief summary: The Swiss Hemophilia Registry will collect data on the prophylactic and therapeutic use of factor concentrates in patients with hemophilia and other severe bleeding disorders in Switzerland.


Eligibility criteria: Inclusion Criteria:

Diagnosis of hemophilia or other severe bleeding disorders. Signed inform consent

Exclusion Criteria:

None

Primary outcomes:
measure: Number of incidence of disease and inhibitor development
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Aarau
country: Switzerland
facility: Kantonsspital Aarau Zentrum für Onkologie/Hämatologie und Transfusionsmedizin
city: Aarau
country: Switzerland
facility: Kinderklinik
city: Basel
country: Switzerland
facility: Universitätsspital Basel Diagnostische Hämatologie
city: Basel
country: Switzerland
facility: Universitätskinderspital beider Basel (UKBB) Abteilung Onkologie/Hämatologie
city: Bellinzona
country: Switzerland
facility: Ospedale San Giovanni
city: Bellinzona
country: Switzerland
facility: Servizio di Ematologia Ospedale Regionale di Bellinzona e Valli
city: Bern
country: Switzerland
facility: Inselspital, Universitätsspital Bern Poliklinik für Hämatologie
city: Chur
country: Switzerland
facility: Kantonspital Graubünden
city: Genève
country: Switzerland
facility: Unité d'Hémostase HUG
city: Genève
country: Switzerland
facility: Unité d'Oncologie-Hématologie pédiatrique, Hôpital des Enfants HUG
city: Lausanne
country: Switzerland
facility: Centre Hospitalier Universitaire Vaudois Service d'Hématologie
city: Lausanne
country: Switzerland
facility: Policlinique d'onco-hématologie péd., CHUV
city: Luzern
country: Switzerland
facility: Kantonsspital Luzern Abteilung Hämatologie
city: Luzern
country: Switzerland
facility: Kinderspital Luzern
city: Sion
country: Switzerland
facility: Kinder und Erwachsenenzentrum Sion Service Régional Valaisan de Transfusion Sanguine CRS
city: St. Gallen
country: Switzerland
facility: Ostschweizer Kinderspital St. Gallen
city: St. Gallen
country: Switzerland
facility: Kantonspital St. Gallen
city: Zürich
country: Switzerland
facility: University Children's Hospital
city: Zürich
country: Switzerland
facility: University Hospital Zürich
Study officials:
References:
Clinical trial NCT01845350: Safety of Autologous M2 Macrophage in Treatment of Non-Acute Stroke Patients
Official title: Safety and Feasibility of Autologous M2 Macrophage Transplantation in Treatment of Non-Acute Stroke Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Ischemic Stroke
Hemorrhagic Stroke
Lead sponsor: Siberian Branch of the Russian Academy of Medical Sciences
Sponsor class: OTHER
First posted: 2013-05-03
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether M2 macrophages are safe and feasible in the treatment of non-acute stroke patients

Detailed description: Our primary hypothesis is that autologous M2 macrophage transplantation via intrathecal introduction is feasible and safe after non-acute stroke. Our secondary hypothesis is that autologous M2 macrophage transplantation is associated with improved neurological outcome after non-acute stroke

Eligibility criteria: Inclusion Criteria:

* Computed tomography confirmed ischemic or hemorrhagic stroke
* Duration since stroke onset more than 3 and less than 12 months
* Age between 18 and 75 years old
* Persistent neurological deficits more than 4 points in NIHSS stroke scale
* Signed informed consent

Exclusion Criteria:

* The history of previous stroke
* Seizures
* Thrombophilias or primary hematological diseases
* Malignancy
* Hepatic or renal dysfunctions
* Hemodynamic or respiratory instability
* Autoimmune disease
* HIV or uncontrolled bacterial, fungal, or viral infections
* Pregnancy
* Participation in other clinical trials

Primary outcomes:
measure: The number of patients with severe adverse events
timeFrame: 1-3 days, 6 months
Secondary outcomes:
measure: Improvement of functional outcome in National Institutes of Health Stroke Scale (NIHSS)
timeFrame: 1-3 days, 6 months
measure: Improvement in Barthel Index
timeFrame: 1-3 days, 6 months
measure: Improvement in modified Rankin scale
timeFrame: 1-3 days, 6 months
Other outcomes:
measure: Number of patients with recurrent vascular episodes
timeFrame: 1-3 days, 6 months
Locations:
city: Novosibirsk
country: Russian Federation
facility: Research Institute of Clinical Immunology, Russian Academy of Medical Sciences (Siberian Branch)
Study officials:
affiliation: Research Institute of Clinical Immunology, Russian Academy of Medical Sciences (Siberian Branch)
name: Elena R. Chernykh, MD, PhD
role: STUDY_CHAIR
References:
citation: Chernykh ER, Shevela EY, Starostina NM, Morozov SA, Davydova MN, Menyaeva EV, Ostanin AA. Safety and Therapeutic Potential of M2 Macrophages in Stroke Treatment. Cell Transplant. 2016;25(8):1461-71. doi: 10.3727/096368915X690279. Epub 2015 Dec 14.
Clinical trial NCT02438150: The Effectiveness of an On-line Training Program on Hospital Medical Staff to Improve Fire Knowledge
Official title: The Effectiveness of an On-line Training Program on Hospital Medical Staff to Improve Fire Knowledge
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Fire
Keywords: Disaster
Training
Lead sponsor: The Hong Kong Polytechnic University
Sponsor class: OTHER
First posted: 2015-05-08
Enrollment: 128
Sex: ALL
Minimum age (years): 20
Maximum age (years): 59
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: Objective: To investigate the effectiveness of an online training program on medical staff in five public hospitals located in Sichuan, Yunnan, Hubei, and Fujian Provinces of China, on improving fire knowledge.

Methods: Participants will be randomly divided into control (receiving non-fire video training) and intervention (receiving hospital fire video training) groups. All participants will complete a questionnaire of fire knowledge before and after receiving the training.

Hypothesis: If the online training is effective, it can be promoted as a convenient and effective use of training and be promoted to other hospitals.


Eligibility criteria: Inclusion Criteria:

* Physicians or nurses working in the recruiting hospitals

Exclusion Criteria:

Primary outcomes:
measure: Change of fire knowledge
timeFrame: Participants will complete the questionnaire 5 minutes before the start of and 1 minute after watching the video which last for 30 minutes, and the change of fire knowledge will be computed.
Secondary outcomes:
Other outcomes:
Locations:
city: Chengdu
country: China
facility: Sichuan Hospital
state: Sichuan
Study officials:
References:
citation: Lee PH, Fu B, Cai W, Chen J, Yuan Z, Zhang L, Ying X. The effectiveness of an on-line training program for improving knowledge of fire prevention and evacuation of healthcare workers: A randomized controlled trial. PLoS One. 2018 Jul 5;13(7):e0199747. doi: 10.1371/journal.pone.0199747. eCollection 2018.